• 1
    Oshima A, Kuroishi T, Tajima K. Cancer statistics in Japan, 2004. -Mortality, incidence and survival. Tokyo: Shinohara Shinsho, 2004.
  • 2
    Nakagawa-Okamura C, Sato S, Tsuji I, et al. Effectiveness of mass screening for endometrial cancer. Acta Cytol. 2002; 46: 277283.
  • 3
    Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol. 2001; 22: 217220.
  • 4
    Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003; 102: 718725.
  • 5
    [No authors listed.] FIGO news. Int J Gynecol Obstet. 1989; 28: 189193.
  • 6
    Kimura F, Watanabe J, Hata H, et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol. 2003; 130: 161168.
  • 7
    Hunt CM, Ellis IO, Elston CW, Locker A, Pearson D, Blamey RW. Cytological grading of breast carcinoma—a feasible proposition? Cytopathology. 1990; 1: 287295.
  • 8
    Taniguchi E, Yang Q, Tang W, et al. Cytologic grading of invasive breast carcinoma. Correlation with clinicopathologic variables and predictive value of nodal metastasis. Acta Cytol. 2000; 44: 587591.
  • 9
    Taniguchi E, Yoshimura G, Yang Q, et al. Cytologic grade of breast carcinoma [in Japanese with English abstract]. J Jpn Soc Clin Cytol. 2002; 41: 388393.
  • 10
    Ciatto S, Bonardi R, Herd-Smith A, Cariaggi P, Confortini M, Bulgaresi P. Prognostic value of breast cancer cytologic grading: a retrospective study of 213 cases. Diagn Cytopathol. 1993; 9: 160163.
  • 11
    Ohno E, Kuramoto H. Diagnosis of the histological grading of endometrial carcinoma by cytology [in Japanese with English abstract]. J Jpn Soc Clin Cytol. 1988; 27: 449458.
  • 12
    Salvesen HB, Iversen OE, Akslen LA. Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer. 1998; 83: 956964.
  • 13
    Sorbe B, Risberg B, Thornthwaite J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer. 1994; 4: 94100.
  • 14
    Van der Putten HW, Baak JP, Koenders TJ, Kurver PH, Stolk HG, Stolte LA. Prognostic value of quantitative pathologic features and DNA content in individual patients with Stage I endometrial adenocarcinoma. Cancer. 1989; 63: 13781387.
  • 15
    Jones MW, Kounelis S, Hsu C, et al. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. Int J Gynecol Pathol. 1997; 16: 354360.
  • 16
    Steiner E, Eicher O, Sagemuller J, et al. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer. 2003; 13: 197203.
  • 17
    Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic L. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol. 2004; 93: 3440.
  • 18
    Arnett-Mansfield R, deFazio A, Wain GV, et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 2001; 61: 45764582.
  • 19
    Sakaguchi H, Fujimoto J, Bao LH, Nakagawa Y, Tamaya. T. Drastic decrease of progesterone receptor form B but not A mRNA reflects poor patient prognosis in endometrial cancers. Gynecol Oncol. 2004; 93: 394399.